| [1] |
Regua AT，Najjar M，Lo HW.RET signaling pathway and RET inhibitors in human cancer[J].Front Oncol，2022（12）：932353.
|
| [2] |
Olmedo ME，Cervera R，Cabezon-Gutierrez L，et al.New horizons for uncommon mutations in non-small cell lung cancer：BRAF，KRAS，RET，MET，NTRK，HER2[J].World J Clin Oncol，2022，13（4）：276-286.
|
| [3] |
Chi X，Michos O，Shakya R，et al.Ret-dependent cell rearrangements in the Wolffian duct epithelium initiate ureteric bud morphogenesis[J].Dev Cell，2009，17（2）：199-209.
|
| [4] |
de Graaff E，Srinivas S，Kilkenny C，et al.Differential activities of the RET tyrosine kinase receptor isoforms during mammalianembryogenesis[J].GenesDev，2001，15（18）：2433-2444.
|
| [5] |
Tsuzuki T，Takahashi M，Asai N，et al.（1995）Spatial and temporal expression of the ret proto-oncogene product in embryonic，infant and adult rat tissues[J].Oncogene，1995，10（1）：191-198.
|
| [6] |
Kohno T，Tabata J，Nakaoku T.REToma：a cancer subtype with a shared driver oncogene[J].Carcinogenesis，2020，41（2）：123-129.
|
| [7] |
Kato S，Subbiah V，Marchlik E，et al.RET aberrations in diverse cancers：next-generation sequencing of 4，871 patients[J].Clin Cancer Res，2017，23（8）：1988-1997.
|
| [8] |
Liu X，Hu X，Shen T，et al.RET kinase alterations in targeted cancer therapy[J].Cancer Drug Resist，2020，3（3）：472-481.
|
| [9] |
Yoh K，Seto T，Satouchi M，et al.Final survival results for the LURET phase Ⅱstudy of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer[J].Lung Cancer，2021，155：40-45.
|
| [10] |
Zheng Q，Fang W，Huang Y，et al.Identification of a novel KIF5B-RET，ABHD17C-RET double-fusion variant in lung adenocarcinoma and response to cabozantinib[J].J Thorac Oncol，2020，15（8）：e132-e133.
|
| [11] |
Mehta M，Griffith J，Panneerselvam J，et al.Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage[J].Int J Radiat Biol，2021，97（8）：1109-1120.
|
| [12] |
Tian Z，Niu X，Yao W.Receptor tyrosine kinases in osteosarcoma treatment：Which is the key target?[J].Front Oncol，2020，10：1642.
|
| [13] |
Hida T，Velcheti V，Reckamp KL，et al.A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma[J].Lung Cancer，2019，138：124-130.
|
| [14] |
Subbiah V，Cassier PA，Siena S，et al.Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial[J].Nat Med，2022，28（8）：1640-1645.
|
| [15] |
国家药品监督管理局.国家药监局附条件批准普拉替尼上市[EB/OL].（2021-03-24）[2023-09-13].https://www.nmpa.gov.cn/yaowen/ypjgyw/20210324140443175.html.
|
| [16] |
苗会青，姚明宏，王雨宁，等.抗肿瘤创新药普拉替尼不良反应信号挖掘与分析[J].中国现代应用药学，2022，39（22）：2975-2980.
|
| [17] |
Tieu C，Breder CD.A critical evaluation of safety signal analysis using algorithmic standardised MedDRA queries[J].Drug Saf，2018，41（12）：1375-1385.
|
| [18] |
杨芝芳，尹小娟，杨沙，等.基于FAERS 数据库的厄达替尼不良事件信号挖掘与分析[J].现代药物与临床，2023，38（38）：709-713.
|
| [19] |
Verbeek HH，de Groot JWB，Sluiter WJ，et al.Calcitonin testing for detection of medullary thyroid cancer in people with thyroid nodules[J].Cochrane Database Syst Rev，2020，3（3）：CD010159.
|
| [20] |
Ali MA，Shah SS，Ali R，et al.Efficacy and Safety of RET-Specific Kinase Inhibitors in RET-Altered Cancers：A Systematic Review[J].Cancer Invest，2023，41（8）：739-749.
|
| [21] |
Ferlay J，Ervik M，Lam F，et al.Global Cancer Observatory：Cancer Today.GLOBOCAN 2020[DB/OL].（2020）[2023-09-13].https://gco.iarc.fr/today/home.
|
